Search Results

Neurotech Pharmaceuticals, Inc. announces that the U.S. Food and Drug Administration (FDA), has determined that the Biologic License Application (BLA) for NT-501, an investigational encapsulated cell therapy for the treatment of MacTel, is sufficiently complete to permit a substantive review.

Neurotech Pharmaceuticals, Inc., a private clinical stage biotech company, announced today that Alex Gorsky has been elected to Neurotech’s board as Lead Director.

Convergent Research today announced a new $14 million funding commitment from former Google CEO Eric Schmidt to Forest Neurotech, an initiative designed to create next-generation brain-computer-interfaces (BCIs) for individuals with neurological injuries or diseases.

Motif Neurotech announced today an oversubscribed Series A financing of $18.75 million led by Arboretum Ventures.

Motif Neurotech , a clinical-stage company developing minimally invasive bioelectronics for mental health, announces the appointment of Steven Goetz as Chief Technology Officer.

Motif Neurotech, a neurotechnology company developing minimally invasive bioelectronics for mental health, announced today new research published to the preprint server medrxiv that demonstrates a millimeter-sized brain stimulator in a human subject.

Neurotech Solutions continues to revolutionize attentional analytics with MOXOedu, a cloud-based tool that has been calibrated for assessing and profiling human attention

Neurotech Pharmaceuticals, Inc., a clinical stage biotech company, today announced the expansion of its executive team with the appointment of Scott Hunter as Chief Commercial Officer bringing two decades of eyecare experience across both rare disease and specialty markets.

CIONIC, the neurotech inventor pioneering bionic clothing, today announced data showcasing the impact of the FDA-cleared Cionic Neural Sleeve as assistive technology for individuals experiencing difficulty walking due to multiple sclerosis (MS).

Neurotech Pharmaceuticals, Inc., a clinical stage biotech company, today announced positive topline results in two replicative Phase 3 clinical trials with their investigational encapsulated cell therapy (ECT) for the treatment of Macular telangiectasia type 2 (MacTel), an orphan, slowly progressive degenerative disease of the macula that results in gradual deterioration of central vision.